The aim of the study was to determine if biochemical changes indicative of injury, assessed using magnetic resonance spectroscopic imaging (SI), are observed after stereotactic radiosurgery (SRS). The study included patients who underwent SI immediately before and 1, 30, and 90 days following SRS. Short TE spectra (TR/ TE 1000/35 ms) were acquired at the SRS isocenter with a 2D PRESS-CSI sequence on a single 1.5 T scanner. The SRS isodose lines were overlaid on the magnetic resonance imaging slice utilized for SI data acquisition. N-Acetyl aspartate (NAA)/creatine (Cr) and choline (Cho)/Cr ratios were computed for multiple voxels located between the 25 and 50 cGy isodose lines (low dose) and the 200 and 350 cGy isodose lines (medium dose). An analysis of variance and paired ttests compared metabolite levels at different time points. Twelve patients were enrolled, although 3 were excluded secondary to poor spectral data quality or deviations from the prescribed SI protocol. The median number of voxels analyzed from the low-and mediumdose region was 7 and 4, respectively. No significant changes in metabolite peak height ratios over time were seen in the low-dose region, for either NAA/Cr (P 5 .89) or Cho/Cr (P 5 .85). There was no difference in Cho/Cr peak height ratios in the medium-dose region (P 5 .62). There was an increase in the NAA/Cr peak height ratio in the medium-dose region between day 21 and day 130 (P 5 .003), followed by a decline to baseline between days 130 and 190 (P 5 .03). We did not observe a significant decline in NAA/Cr or change in Cho/Cr peak heights in uninvolved brain parenchyma after SRS.
S
tereotactic radiosurgery (SRS) is frequently employed to treat both benign and malignant intracranial diseases, including brain metastases, meningiomas, arteriovenous malformations, and vestibular schwannomas. In this technique, typically 1 large dose of radiation is delivered to a small target using multiple noncoplanar beams or arcs. Toxicity is minimized by tightly conforming the high-dose region to the target. Nonetheless, a large volume of normal brain often receives a low dose of radiation, the consequences of which are unknown.
The deleterious effects of radiation therapy (RT) to the brain are an active area of investigation. The mechanisms of injury are complex, but may involve apoptosis, gene induction, disruption of the blood brain barrier, and injury to the endothelium. 1 Radiation-induced magnetic resonance imaging (MRI) changes, such as T2 signal abnormality, are non-specific and can be seen in a variety of processes including edema, demyelination, and necrosis. 2 Furthermore, central nervous system (CNS) injury after RT may be present despite a normally appearing MRI. 3 Proton magnetic resonance spectroscopic imaging (SI) is an emerging modality to assess CNS injury from a variety of insults including head trauma, 4 ischemic stroke, 5, 6 and multiple sclerosis. 7 For example, several studies have shown that N-acetyl aspartate (NAA), 8 an amino acid present in the brain and a marker of neuron density and activity, decreases in normal brain tissue after conventional RT. 9 -13 Few data exist quantifying SI changes after SRS, let alone relating these changes to clinical parameters. Our aim was to use SI to measure metabolites within brain parenchyma receiving relatively low doses of RT after SRS and correlate these changes with dose and time after treatment.
Materials and Methods
This prospective study was approved by the Duke University Institutional Review Board (7703-05-10R0), and all patients provided informed consent prior to enrollment. Eligible patients were !18 years old, had a life expectancy of !3 months, and were scheduled to receive SRS for a benign or malignant condition. No previous brain irradiation was permitted. Patients with intracranial lesions that would not entail irradiation of enough brain parenchyma for assessment of study objectives (ie, acoustic neuromas), or with tumors in close proximity to the skull, were excluded. Patients who were scheduled, or anticipated to require, additional RT to the brain, including whole brain radiation, within 3 months of SRS were also ineligible. Female patients of childbearing potential were required to have a negative pregnancy test. Immediately prior to SRS (day 21) and on days þ1, þ30, and þ90 after SRS, patients underwent MRI and SI. T1-weighted (TR/TE 500/8) and T2-weighted images (TR/TE 2500/20) were obtained with a 256 Â 128 pixel matrix, 5-mm section thickness, and 2.5 mm intersection gap through the selected region.
All 1 H SI data were obtained on the same 1.5 T GE whole-body MR scanner (GE Medical Sysems, Milwaukee, Wisconsin) using a standard imaging head coil. Images were taken at the SRS isocenter. A short TE point-resolved SI sequence (PRESS-SI, TR/TE 1000/35) was used to localize and acquire the 2D SI data using the standard single-channel head coil. PRESS-SI parameters were selected to deliver isotropic, SI voxels with a nominal volume of 1.0 mL (FOV 24, 24 Â 24 phase encodes, NEX 1, slice thickness 10 mm, scan time 10 minutes). The shim was optimized over the selected PRESS volume. Application of out-of-voxel saturation pulses was used to eliminate residual lipid signal arising from the scalp.
Follow-up axial MRI images were imported into the Radionics (Tyco Healthcare, Burlington, Massachusetts) workstation in the Department of Radiation Oncology. The images were coregistered with MRI and CT scans obtained for SRS planning. The isodose lines indicating dose delivered to the surrounding brain tissue were overlaid on the MRI slice utilized for SI data acquisition.
The characteristics of the SRS dose distribution and magnetic resonance spectroscopy (MRS) voxel size precludes studying a single homogeneous dose level. We were therefore constrained to study a dose range. Since the dose fall-off near the target is exceptionally steep, it was not feasible to accurately study the regions of the brain receiving doses approaching the SRS prescription (1000 -2000 cGy). A medium-dose region of 200-350 cGy was selected because the isodose lines are sufficiently separated by this point, allowing MRS voxels to be completely enclosed within this volume. The region between the 25 and 50 cGy isodose lines was arbitrarily chosen as a low-dose region.
Spectroscopy data were recorded from multiple voxels located between the 25 and 50 cGy isodose lines and between the 200 and 350 cGy isodose lines. Voxels which included the ventricular space, or which were adjacent to the scalp, were not included. We attempted to derive data from 8 voxels from each SI examination for both low-and medium-dose regions for all patients, but this was not always feasible given the isodose line configuration, quality of spectra near the scalp, and proximity to the ventricular system. Peak heights were determined for the resonances of NAA, choline (Cho), and creatine (Cr), corresponding to 2.01, 3.21, and 3.02 ppm, respectively. Metabolite peak height ratios (NAA/Cr and Cho/Cr) were computed separately for each voxel.
A paired t-test was used to compare metabolite levels between different time points at the same dose level. For example, the NAA/Cr ratio in the low-dose region was compared between þ1 and þ30 days for each patient. An analysis of variance was also performed to determine if there were statistically significant changes over time.
Additionally, all patients completed a quality-of-life assessment at baseline and after each MRS examination. The Functional Assessment of Cancer Therapy-Brain (FACT-Br) was developed to assess health-related quality of life in patients with primary brain tumors and is comprised of the FACT-General (FACT-G) and a brain cancer-specific (BrCS) additional concerns subscale.
14 The FACT-G has 4 subscales: a 7-item physical well-being (PWB) subscale, a 7-item social/family wellbeing (SWB) subscale, a 6-item emotional well-being (EWB) subscale, and a 7-item functional well-being (FWB) subscale. 15 All items have Likert-type response scale ranging from 0, "Not at all," to 4, "Very much." Item responses on negatively worded items, such as "I have a lack of energy," are reversed, so that a value of 4 corresponds to the highest (best) quality of life on each question. After reversals are made, responses to items are aggregated to create summary scores for each subscale (PWB, SWB, EWB, FWB, and BrCS), a total FACT-G score (PWB þ SWB þ EWB þ FWB), and a FACT-Br Total score (FACT-G þ BrCS). The Trial Outcome Index (TOI) is the sum of PWB, FWB, and BrCS. Scales with missing items were prorated so long as more than 50% of the questions were answered (80% for the FACT-G total). If 50% or fewer items were answered, the scale score was considered missing.
Descriptive statistics (means, standard deviations, minimum, maximum) were calculated at each time point for all FACT-Br scores and change from baseline. Means (standard deviations) for the FACT-G in the general US population have been published and are 22.7 (5.4) for the PWB, 19.1 (6.8) for the SWB, 19.9 (4.8) for the EWB, 18.5 (6.8) for the FWB, and 80.1 (18.1) for the FACT-G. 16 Minimally important differences (MIDs) have also been established for the FACT-Br: 2 -3 points for the PWB, SWB, EWB, and FWB, and 3-7 points for the FACT-G.
Results
This prospective pilot study enrolled 12 patients. All patients underwent SRS using a linear accelerator, either with conventional arcs (n ¼ 7) or with fixed beams using a micromultileaf collimator (n ¼ 5). The prescription isodose line ranged from 92% to 98% (median, 94%). Three patients were excluded due to poor spectral quality related to targets in or near the posterior fossa (n ¼ 2) or deviations from the prescribed SI protocol (n ¼ 1). Of the 9 evaluable patients, 8 completed all 4 SI examinations. One patient developed progressive brain metastases after the þ30 day SI examination, was taken off protocol, and received whole brain RT. All 12 patients were evaluable for quality-of-life endpoints. Patient characteristics, including the 3 who were excluded, can be found in Table 1 .
The median number of voxels analyzed from the low-dose region was 7 (range, 2 -8). The median number of voxels analyzed from the medium-dose region was 4 (range, [3] [4] [5] [6] [7] [8] . Individual patient data for low-and medium-dose regions are shown graphically in Figs. 1 and 2 , respectively. No significant changes in metabolite peak height ratios over time were seen in the low-dose region, for either NAA/Cr (P ¼ .89) or Cho/Cr (P ¼ .85) (Fig. 3) . Similarly, there was no difference in Cho/Cr ratios in the medium-dose region (P ¼ .62; Fig. 4 ). There was a statistically significant difference in NAA/Cr peak height ratios in the medium-dose region (P ¼ .0007). There was a significant increase in the NAA/Cr ratio between days 21 and þ30 (P ¼ .003) and between days þ1 and þ30 (P ¼ .01). This was followed by a significant decline toward baseline between days þ30 and þ90 (P ¼ .03).
FACT-Br descriptive statistics for all 12 patients are presented in Table 2 . At baseline, patients in this study reported lower EWB and higher SWB compared with the general US population. There was a statistically significant increase compared with baseline in EWB scores at day 30 (P ¼ .002). This means that the increase (2.7 points) is in the range of the MID for this scale. No other changes from baseline were both statistically significant and clinically meaningful.
Discussion

RT and CNS Toxicity
The potentially harmful effects of brain irradiation were first reported in 1930. 17 RT-induced CNS injury is classically divided into 3 clinical phases. Acute injury occurs during RT and is thought to be a result of disruption of the blood brain barrier leading to cerebral edema. Symptoms include increasing headaches, nausea/vomiting, and exacerbation of underlying neurological deficits. The early-delayed phase occurs 1-3 months after RT and is thought to be a result of transient demyelination. The somnolence syndrome and transient cognitive impairment are associated with this phase of injury, which is felt to be largely reversible. Finally, late-delayed injury occurs more than 4-6 months after RT and is thought to be secondary to injury to the vasculature and supporting glial cells. Radiation necrosis and permanent cognitive dysfunction (dementia) are typical of latedelayed injury. More subtle alterations in cognitive dysfunction ranging from mild short-term memory loss to global neuropsychological deficits such as personality change and an overt decrease in IQ are very common and can lead to significant decrease in quality-of-life of patients. These toxicities have been defined after RT is delivered with standard doses and techniques.
In SRS, a relatively low total dose of radiation is utilized (12 -24 Gy), but it is delivered in a single consequences of this are poorly characterized, but could become increasingly important as overall survival continues to improve. Radiobiological studies suggest a region of hypersensitivity to ionizing radiation below about 50 cGy. 18 -20 These studies show that the surviving cell fraction following relatively low doses of radiation is far less than that predicted by the standard linear-quadratic equation. However, the clinical importance of this phenomenon is unclear, and limited studies have suggested that neurocognitive effects of SRS are mild.
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MRS and CNS Toxicity
The most significant, albeit rare, adverse effect of SRS is radionecrosis. This occurs in only a few percent of patients and is generally limited to the tumor bed and immediately adjacent tissue. Changes in metabolite levels, such as the neuronal-related metabolite NAA, may be a more sensitive indicator of CNS toxicity. 1 H-MRS noninvasively measures signals from multiple metabolites within a single measurement period. These metabolites include NAA, Cho, Cr, myo-inositol, and lactate.
In normal brain tissue, the most easily seen signal arises from NAA. NAA is an amino acid which is confined primarily to neurons, 25 and is a marker of neuron density and neuron functionality. 26 The Cho signal arises from mobile Cho and Cho-containing compounds, many of which are present within the cell membrane. An increase in Cho may be indicative of rapid cell turnover (membrane synthesis or degradation) and is associated with demyelinating processes and brain tumors. Cr concentrations are relatively constant under most pathologic conditions and are often used as a "reference" peak to normalize other metabolite signals 27 through the calculation of ratios.
1 H-MRS is commonly used to evaluate injury to the brain from a variety of insults including Alzheimer's and other dementias, 27 -29 temporal lobe epilepsy, 30 -32 multiple sclerosis, 7, 33 ischemic stroke, 5, 6 and traumatic brain injury. 4 In Alzheimer's disease, total NAA levels are decreased throughout the cortex 29 and NAA/Cr levels are decreased compared with age-matched controls. 28 In temporal lobe epilepsy, NAA/Cr has been shown to be reduced in the atrophic hippocampus as well as the contralateral hippocampus appearing normal on MRI, but with abnormal EEG features. 34 In patients with secondary progressive multiple sclerosis, NAA/Cr levels in normal-appearing white matter are decreased. 7 
MRS after Conventional RT
Biochemical changes within the brain after RT have been documented by several investigators. One of the earliest studies to utilize MRS in this manner was from Szigety et al. 35 In a prospective study, 10 patients with brain tumors treated with RT underwent single-voxel MRS before and serially after RT. Both low-and high-dose regions were analyzed. MRS was repeated regularly for up to 4 months after RT. Compared with healthy (and younger) volunteers, both NAA/Cr and Cho/Cr levels were lower in study patients prior to RT. Cho/Cr levels rose after RT, most noticeably in the high-dose region, but NAA/Cr levels were stable. It was postulated that RT may damage oligodendrocytes which produce the Cho-rich myelin sheath.
In the study by Szigety et al., 35 there was no statistically significant change in NAA/Cr levels. However, multiple subsequent studies have shown that conventionally fractionated RT is associated with a decline in NAA/Cr levels. In a prospective study, Esteve et al. 36 obtained MRS scans before RT and at 1, 4, and 8 months after the start of RT. Eleven patients were studied, 10 of whom had malignant gliomas and were treated with 60 Gy without chemotherapy. Metabolite concentrations were measured in the contralateral cerebral hemisphere receiving 20 -50 Gy. NAA/Cr levels were lower 1 month after initiating RT. Cho/Cr values did not change over time. Similarly, Rutkowski et al. 9 studied 43 patients treated for gliomas with RT (2 Gy daily to 60 Gy), all of whom were without evidence of disease progression at the time of follow-up. MRS was obtained before and at 9 months after RT. Spectra were obtained from 3 dose regions (,6, 21 -39, and 60 Gy). There was a statistically significant, dosedependent decrease in NAA/Cr levels. For the high-dose regions (60 Gy), there was a significant increase in the Cho/Cr signal. Multiple other studies have shown a decrease in NAA/Cr levels in normal brain after conventional external beam RT. 10 -13,37 As detailed above, several studies have shown that NAA/Cr values decrease after RT. The clinical implications of this remain unclear. In a cohort of surviving children and young adults with acute lymphoblastic leukemia, there was a statistically significant decreasing trend of NAA/Cr values over time. 37 However, NAA/Cr values did not correlate with academic achievement. In a study of 8 patients, Movsas et al. 13 reported that whole brain RT was associated with a decrease in whole-brain NAA, but there were no corresponding changes in Mini-Mental Status Examination scores. However, more sensitive neuropsychologic testing may have detected clinically relevant changes.
MRS after SRS
While several investigators have observed biochemical changes in the normal brain after conventionally fractionated RT, few have studied such after SRS. Hajek et al. 38 evaluated 6 patients treated with SRS for mesial temporal lobe epilepsy with serial MRI and MRS examinations. MRI/MRS was performed every 6 -12 months after SRS for a period of 3 years. NAA levels within the affected temporal lobe were lower prior to SRS when compared with both the contralateral temporal lobe and healthy controls. NAA levels in the treated temporal lobe decreased as early as 6 months after SRS. Furthermore, this was observed approximately 6 months prior to the development of atrophy on conventional MRI. NAA levels in the contralateral temporal lobe increased after SRS, perhaps secondary to normalization of neuronal function associated with seizure elimination. No biochemical changes were otherwise noted outside the target volume.
This study is unique in many ways. First, it is the only study to look at regions of brain receiving very low doses of RT (25 -50 cGy). During SRS, depending on the location of the lesion and the SRS planning technique, a significant volume of brain can receive a low dose of RT. We did not demonstrate a decrease in NAA/Cr after SRS in regions of the brain receiving a very low dose of RT (25 cGy). In regions of the brain receiving between 200 and 350 cGy, there was actually an increase in NAA/Cr values followed by subsequent normalization. The significance of this, if at all, is unclear. Similarly, we did not see any significant differences in Cho/Cr values, either in the low-dose or in the mediumdose regions. It is not feasible to utilize MRS in the highest dose region, inasmuch as the dose fall-off is quite steep and the nominal SI voxel size is 1 cm.
Second, all of our patients had either benign conditions (AVMs, meningiomas) or brain metastases. Many studies examining MRS include patients with malignant gliomas. The possible infiltration of tumor cells into healthy-appearing brain may influence the spectra. Third, many studies compare biochemical changes after RT to values obtained from healthy volunteers. In our study, patients underwent MRS immediately prior to SRS, thus serving as their own controls.
We acknowledge that there are weaknesses in our data analysis. First, MRS is a volume-averaging imaging technique. Further, due to the characteristics of the SRS dose distribution, we were constrained to study a dose range. Both of these issues may have compromised our ability to detect small local changes in metabolite peak height ratios. Second, the MRS protocol selected used a TE time of 35 ms. A longer TE time (144 ms) would have acquired data with a simpler spectral pattern for analysis. Third, the tools available for postprocessing only allowed us the most simple of spectral peak measures, namely metabolite peak height values. Changes in peak height due to underlying macromolecular changes, residual water and lipid signals, and spectral linewidth variations can confound measurements of peak heights and were not accounted for in this study. A more sophisticated analysis of the data, making use of a prior knowledge based optimization to a spectral model (such as LC Model) can account for these confounding effects and might have been able to identify small physiological changes in the metabolites of interest. A final weakness in our protocol design was the small number of patients and the lack of long-term follow-up. Nevertheless, it is reassuring that no gross changes indicative of injury were noted in our study. In addition, patient quality of life was not decreased in this study. However, it will be important to assess more carefully for subtle changes in neurocognitive function which may be undetected by a simple QOL assessment, particularly in assessing the impact of low-dose RT.
Conclusions
We did not demonstrate a significant decline in NAA/Cr peak height ratios in regions of the brain receiving unintended low-dose radiation over the first 90 days following SRS. While this is encouraging, further work with longer follow-up may be helpful. 
